Apoptosis and its role in the myelodysplastic syndromes: Implications for disease natural history and treatment

Leukemia Research

Volumn 22, Issue 12, 1998, Pages 1123-1136

  Greenberg, Peter L ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Apoptosis; Hematopoiesis; MDS; Myelodysplastic syndrome; Oncogenes

Indexed keywords

AMIFOSTINE; CIPROFLOXACIN; CYTOKINE; DEXAMETHASONE; ERYTHROPOIETIN; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOPROTEIN; PENTOXIFYLLINE; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CELL SURVIVAL; CYTOPENIA; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; LEUKEMOGENESIS; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW;

EID: 0032408713     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00112-X     Document Type: Article

References (164)

1. Greenberg PL. The myelodysplastic syndromes. In: Hoffman R, Benz E, Shattil S, Furie B, Cohen H, editors. Hematology: Basic Principles and Practice, 2nd ed. New York: Churchill Livingstone, 1994:1098-1121.
2. Greenberg P.L. Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin Hematol. 33:1996;163-175.
3. Koeffler H. Myelodysplastic syndromes (preleukemia). Semin Haematol. 23:1986;284.
4. Bennett J., Catovsky D., Daniel M., Flandrin G., Galton D., Gralnick H., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 51:1982;189.
5. Sanz G.F., Sanz M.A., Vallespi T., Canizo M. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood. 74:1989;395-408.
6. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079.
7. Jacobs R.A., Cornbleet M., Vardiman J., Larson R., LeBeau M.M., Rowley J.D. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood. 67:1986;1765.
8. Yunis J.J., Lobell M., Arnesen M.A., Oken M.M., Mayer M.G., Rydell R.E., Brunning R.D. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol. 68:1988;189.
9. Bartram C.R. Molecular genetic aspects of myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease. Br J Haematol. 74:1990;408.
10. Gallagher A., Darley R., Padua R. The molecular basis of myelodysplastic syndromes. Haematologica. 82:1997;191.
11. Clark D.M., Lampert I.A. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective haematopoiesis. Leuk Lymphoma. 2:1990;415.
12. Raza A., Gezer S., Mundle S., Gao X.-Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Lowe J.B.M., Khan Z., Chaney C., Showel J., Gregory S., Preisler H. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 86:1995;268.
13. Raza A., Mundle S., Iftikhar A., Gregory S., Marcus B., Khan Z., Alvi S., Shetty V., Damerson S., Wright V., Adler S., Loew J.M., Shott S., Ali S.N., Preisler H. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol. 48:1995;143.
14. Rajapaksa R., Ginzton N., Rott L., Greenberg P.L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood. 88:1996;4275.
15. Wyllie A.H., Kerr J.F.R., Currie A.H. Cell death: the significance of apoptosis. Int Rev Cytol. 68:1980;251.
16. Wyllie A.H. Cell death. Int Rev Cytol. 17:1987;755.
17. Walker N.I., Harmon B.V., Gobe G.C., Kerr J.F.R. Patterns of cell death. Methods Achiev Exp Pathol. 13:1988;18.
18. Cohen J.J., Duke R.C. Glucocoticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immuol. 123:1984;3842.
19. Wyllie A.H. Glucocorticoid-induced thymocyte apoptosis is associated with endonuclease activation. Nature. 284:1980;555.
20. Vaux D. Toward understanding of the molecular mechanism of physiological cell death. Proc Natl Acad Sci USA. 90:1993;786.
21. Chen-Levy Z., Nourse J., Cleary M.L. The bcl-2 candidate protooncogene product is a 24-kilodalton integral membrane protein highly expressed in lymphoid cell lines and lymphoma carrying the t(14;18) translocation. Mol Cell Biol. 9:1989;701.
22. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334.
23. Nunez G., London L., Korsmeyer S. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cells lines. J Immunol. 144:1990;3602.
24. Larsen C.J. The bcl-2 gene: prototype of a gene family that controls programmed cell death (apoptosis). Ann Genet. 37:1994;121.
25. Reed J.C. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 34:1997;9.
26. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119.
27. Askew D.S., Ashmun R.A., Simmons B.C., Cleveland J.L. Constitutive c-myc expression in IL-3 dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 6:1991;1915.
28. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847.
29. Cleveland J.L., Ihle J.N. Contenders in FasL/TNF signaling. Cell. 81:1995;479.
30. Nagata S., Golstein P. The fas death factors. Science. 267:1995;1499.
31. Reed J.C. Dysregulation of apoptosis in non-Hodgkins lymphoma: Toward a molecular understanding of Bcl-2. Adv Leuk Lymphoma. 7:1997;3.
32. Rodriguez-Tarduchy G., Collins M., Lopez-Rivas A. Regulation of apoptosis in interleukin-3 dependent hemopoietic cells by interleukin-3 and calcium ionophores. EMBO J. 9:1990;2997.
33. Williams G.T., Smith C.A., Spooncer E., Dexter T.M., Taylor D.R. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature. 343:1990;76.
34. Koury M. Programmed cell death (apoptosis) in hematopoiesis. Exp Hematol. 20:1992;391.
35. Han J.H., Gileadi C., Rajapaksa R., Kosek J., Greenberg P.L. Modulation of apoptosis in human myeloid leukemic cells by granulocyte-macrophage colony-stimulating factor. Exp Hematol. 23:1995;265.
36. Krajewski S., Krajewska M., Shabaik A.et al. Immunohistochemical analysis of in vivo patterna of Bcl-X expression. Cancer Res. 54:1994;5501.
37. Krajewski S., Bodrug S., Krajewska M.et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol. 146:1995;1309.
38. Zhia H., Fisk H.A., Yaffe M.P., Mahajan N., Herman B., Reed J.C. Structure-function comparisons of the proapoptotic protein Bax in yeast and mammalian cells. Mol Cell Biol. 16:1996;6494.
39. Jurgensmeier J.M., Krajesski S., Armstrong R.C.et al. Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe. Mol Biol Cell. 8:1997;325.
40. Henderson, Huen D., Rowe M., Dawson C., Johnson G., Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Nat Acad Sci USA. 90:1993;8479.
41. Rao L., Debbas M., Sabbatini P., Hockenberry D., Korsmeyer S., White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA. 89:1992;9974.
42. Cheng E.H., Nicholas J., Bellows D.S.et al. A Bcl-2 homologue encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci USA. 94:1997;690.
43. Hengartner M.O., Horvitz H.R.C. elegans cell survival gene ced-9 encodes a functional homodimer of the mammalian proto-oncogene bcl-2. Cell. 76:1994;665.
44. Wu D., Waller H., Nunez G. Interaction and regulation of subcellular localization of Ced4 by Ced9. Science. 275:1997;1126.
45. Miyashita T., Reed J. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293.
46. Yin C., Knudson C., Korsmeyer S., Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385:1997;637.
47. Krajewski S., Tanaka S., Takayama S., Schibler M.J., Fenton W., Reed J.C. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outher mitochondrial membranes. Cancer Res. 53:1993;4701.
48. Petit P.X., Susin S.A., Zamzami N., Mignotte B., Kroemer G. Mitochondria and programmed cell death: back to the future. FEBS Lett. 396:1996;7.
49. Minn A.J., Velez P., Schendel S.L., Liang H., Muchmore S.W., Fesik S.W., Fill M., Thompson C.V. Bcl-x forms an ion channel in synthetic lipid membranes. Nature. 385:1997;353.
50. Marchetti P, Castedo M, Susin SA et al., Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 184:1155.
51. Bernardi P., Borekemeier K.M., Pfeiffer D.R. Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioeng Biomembr. 26:1994;509.
52. 2+. Oncogene. 12:1996;2259.
53. Liu X., Kim C.N., Yang J., Jemmerson T., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 86:1996;147.
54. Susin S.A., Zamzami N., Castedo M.et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med. 184:1996;1331.
55. Zou H., Henzel W.J., Liu X., Lutschg A., Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 90:1997;405.
56. Oltvai Z., Milliman C., Korsmeyer S. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programed cell death. Cell. 74:1993;609.
57. Zha H., Aime-Sempe C., Sato T., Reed J.C. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem. 271:1996;7440.
58. Korsmeyer S.J. Regulators of cell death. Trends Genet. 11:1995;101.
59. Rao L., White E. Bcl-2 and the ICE family of apoptotic regulators: making a connection. Curr Opin Genet Dev. 7:1997;52.
60. Han J., Sabbatini P., White E. Induction of apoptosis by human Nbk/Bik, a BH3 containing E1B 19K interacting protein. Mol Cell Biol. 16:1996;5857.
61. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nunez G., Thompson C.B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597.
62. Chittenden T., Flemington C., Houghton A., Ebb R., Gallo G., Elangovan B., chinnadurai G., Lutz R. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J. 14:1995;5589.
63. Hunter J., Bond B., Parslow T. Functional dissection of the human Bcl-2 protein: Sequence requirements for inhibition of apoptosis. Mol Cell Biol. 16:1996;877.
64. Ryan J., Prochownik E., Gottlieb C.et al. c-myc and bcl-2 modulate p53 subcellular function by altering p53 trafficking during the cell cycle. Proc Natl Acad Sci USA. 91:1994;5857.
65. Chang BS, Minn AJ, Muchmore SW, Fesik SW, Thompson CB. Identification of a novel regulatory domain in Bcl-X(L) and Bcl-2. EMBO J 1997;16:968.
66. Sakai N., Ogiso Y., Fujita H., Watari H.J., Koike T., Kuzumaki N. Induction of apoptosis by a dominant negative H-ras mutant (116y) in K562 cells. Exp Cell Res. 37:1994;121.
67. Wang H.G., Miyashita T., Takayama S.et al. Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene. 9:1994;2751.
68. Wang H.G., Millan J.A., Cox A.D.et al. R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism. J Cell Biol. 129:1995;1103.
69. Rajapaksa R., Bhatia S., Alluri N., Greenberg P.L. Regulation and function of Fas and Fas ligand expression in human myeloid leukemia cells. Blood. 90(Suppl. 1):1997;196b.
70. Lotem J., Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotheraphy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Diff. 4:1993;41.
71. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1999;440.
72. Fanidi A., Harrington E.A., Evan G.I. Interaction between c-myc and bcl-2 protooncogenes: A noval paradigm for oncogene cooperation. Nature. 359:1992;554.
73. Bissonnette R.P., Echeverrri F., Mahboudi A., Green D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature. 359:1992;552.
74. Shi Y., Glynn J.M., Guilbert L.J., Cotter T.G., Bissonnette R.P., Green D.R. Role for c-myc in activation induced apoptotic cell death in T-cell hybridomas. Science. 257:1992;213.
75. Chiou S., Rao L., White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol. 14:1994;2556.
76. Clarke A.R., Purdie C.A., Harrison D.J.et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1993;849.
77. Prokocimer M., Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood. 84:1994;2391.
78. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature. 352:1991;345.
79. Gottlieb E., Haffner R., von Ruden T., Wagner E.F., Oren M. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J. 13:1994;1368.
80. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054.
81. White E. Life, death and the pursuit of apoptosis. Genes Dev. 10:1996;1.
82. Martin S., Green D. Protease activation during apoptosis: death by a thousand cuts? Cell. 82:1995;349.
83. Patel T., Gores G., Kaufman S. The role of proteases during apoptosis. FASEB J. 10:1996;587.
84. Yuan J., Shaham S., Ledoux S., Ellis H.M., Horvitz J.R. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell. 75:1993;641.
85. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J. Human ICE/CED-3 protease nomenclature. Cell. 87:1996;171.
86. Kuida K., Lippke J.A., Ku G., Harding M.W., Livingston D.J., Su M.S., Flavell R.A. Altered cytokine export and apoptosis in mice deficient in interleukin-1β converting enzyme. Science. 267:1995;2000.
87. Kuida K., Zheng T.S., Na S., Kuan C.Y., Karasuyama H., Rakic P., Flavell R.A. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature. 384:1996;368.
88. Bump N.J., Hackett M., Hugunin M., Seshagiri S., Brady K., Chen P., Ferenz C., Franklin S., Ghayur T., Li P., Licari P., Mankovich J., Shi L., Greenberg A., Miller L.K., Wong W.W. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science. 269:1995;1885.
89. Komiyama T., Ray C.A., Pickup D.J., Howard A.D., Thornberry N.A., Peterson E.P., Salvesen G. Inhibition of interleukin-1β converting enzyme by the cowpox virus serpin CrmA. J Biol Chem. 269:1994;19331.
90. Zamzami N., Susin S., Marchetti P., Hirsch T., Gomez-Monterrey I., Castedo M., Kroemer G. Mitochondrial control of nuclear apoptosis. J Exp Med. 183:1996;1533.
91. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell. 85:1996;803.
92. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J.D., Zhang M., Gentz R., Mann M., Krammer P.H., Peter M.E., Dixit V.M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:1996;817.
93. Yang X., Khosravi-Far R., Chang H., Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell. 89:1997;1067.
94. Rao L., Perez D., White E. Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol. 135:1996;1441.
95. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D. The release of cytochrome c from mitochrondia: A primary site for Bcl-2 regulation of apoptosis. Science. 275:1997;1132.
96. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.-L., Jones D.P., Want X. Prevention of apoptosis by Bcl-2 release of cytochrome c from mitochondria blocked. Science. 275:1997;1129.
97. Beg A.A., Baltimore D. An essential role for NF-KB in preventing TNF-α induced cell death. Science. 274:1996;782.
98. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-α-induced apoptosis by NF-KB. Science. 274:1996;787.
99. Wang C.Y., Mayo M.W., Baldwin A.S. Jr. TNF and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-KB. Science. 274:1996;784.
100. Ormerod MG. Analysis of DNA. General methods. In: Ormerod MG, editor. Flow Cytometry. A Practical Approach. Oxford: IRL press at Oxford University Press, 1990:69.
101. Van Engeland M., Nieland L.J., Ramaekers F.C., Schutte B., Reutelingsperger C.P. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 31:1998;1.
102. Di Nicola M., Bregni M., Siena S., Ruffini P.A., Milanesi M., Ravagnani F., Gianni A.M. Combined negative and positive selection of mobilized CD34 blood cells. Br J Haematol. 94:1996;716.
103. Hockenbery D., Zutter M., Hickey W., Nahm M. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA. 88:1991;6961.
104. Gaulard P., d'Agay M.-F., Peuchmaur M., Brousse N., Gisselbrecht C., Solal-Celigny P., Diebold J., Mason D. Expression of the bcl-Y 2 gene product in follicular lymphoma. Am J Pathol. 140:1992;1089.
105. Schena M., Larsson L.-G., Gottardi D., Gaidano G. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood. 79:1992;2981.
106. McDonnell T.J., Deane N., Platt F.M., Nunez G., Jaeger U., McKearn J.P., Korsmeyer S.J. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 57:1989;79.
107. McDonnell T., Korsmeyer S. Progression from lymphoid hyperplasia to high- grade malignant lymphoma in mice transgenic for the t(14;18). Nature. 349:1991;254.
108. Aguilar-Santelises M., Rottenberg M., Lwein N., Mellstedt H., Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 69:1996;114.
109. Kastan M.B., Stone K.D., Civin C.I. Nuclear oncoprotein expression as a function of lineage, differentiation stage and proliferative status of normal human hematopoietic cells. Blood. 74:1989;1517.
110. Meijerink J., Smetsers T., Sloetjes A., Linders E., Mensink E. Bax mutations in cell lines derived from hematological malignancies. Leukemia. 9:1995;1828.
111. Meijerink J., Mensink E., Wang K., Sedlak T., Sloetjes A., De Witte T., Waksmann G., Korsmeyer S. Hematopoietic malignancies demonstrate loss-of-function mutations of Bax. Blood. 91:1998;2991.
112. Delia D., Aiello A., Soligo D., Fontanella E. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood. 79:1992;1291.
113. Porwit-MacDonald A., Ivory K., Wilkinson S., Wheatley K., Wong L., Janossy G. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia. 9:1995;1191.
114. Campos L., Rouault J.-P., Sabiolo O., Oriol P., Roubi N., Vasselan C., Archimbaud E. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091.
115. Bradbury D.A., Russell N.H. Comparative quantitative expression of bcl-2 by normal and leukemic myeloid cells. Br J Haematol. 91:1995;374.
116. Campos L., Sabido O., Rouault J.-P., Guyotat D. Effects of bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood. 84:1994;595.
117. Banker D.E., Groudine M., Norwood T., Appelbaum F.R. Measurement of spontaneous and therapeutic agent-induced apoptosis with bcl-2 protein expression in acute myeloid leukemia. Blood. 89:1997;243.
118. Maung Z.T., MacLean F.R., Reid M.M., Pearson A.D.J., Proctor S.J., Hamilton P.J., Hall A.G. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol. 88:1994;105.
119. San Miguel J.F., Martinez A., Macedo A., Vidriales M.B., López-Berges C., González M., Caballero D., Garcia-Marcos M.A., Ramos F., Fernández-Calvo J., Calmuntia M.J., Diaz-Mediavilla J., Orfao A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 90:1997;2465.
120. Del Canizo M.C., Galende J., Mota A., Orfao A., Martinez A., Almeida J., San Miguel J.F. In leukemic hematopoiesis CD34 antigen does not have the same significance as it does in normal hematopoiesis. Leuk Res. 21:1997;651.
121. Bogdanovic A.D., Trpinac D.P., Jankovic G.M., Bumbasirevic V.Z., Obradovic M., Colovic M.D. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia. 11:1997;656.
122. Mundle S., Iftikhar A., Shetty V., Dameron S., Wright-Quinones V., Marcus B., Lowe J., Gregory S., Raza A. Novel in situ double labeling for simultaneous detection of proliferation and apoptosis. J Histochem Cytochem. 42:1994;1533.
123. Nagler A., Ginzton N., Negrin R., Bangs D., Donlon T., Greenberg P. Effects of recombinant human granulocyte colony stimulating factor and granulocyte-monocyte colony-stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes. Leukemia. 4:1993;193.
124. Greenberg P.L., Baker S., Link M., Minowada J. Immunologic selection of hemopoietic precursor cells utilizing antibody-mediated plate binding ('panning'). Blood. 65:1985;190.
125. Tsoplou P., Kourakli-Symeonidis A., Thanopoulou E., Orphanos V., Zoumbos N. Apoptosis in patients with myelodysplastic syndromes: Differential involvement of marrow cells in early versus advanced cases and correlation with the expression of apoptosis-related genes. Blood. 90(Suppl 1):1997;203a.
126. Ricciardi M.R., Petrucci M.T., Ariola C., Gregorj C., Mazzola R., Latagliata R., Petti M.C., Tafuri A. High levels of apoptosis characterize RAEB and are lost during leukemic transformation. Blood. 90(Suppl 1):1997;520a.
127. Hellstrom-Lindberg E., Kanter-Lewensohn L., Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res. 21:1997;415.
128. Lepelley P., Campergue L., Grardel N.et al. Is apoptosis a massive process in myelodysplastic syndromes? Br J Haematol. 95:1996;368.
129. Sachs L., Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood. 82:1993;15.
130. Parker J.E., Fishlock K.L., Mijovic A., Pagliucca A., Mufti G. Leukemic progression in myelodysplastic syndromes decreased apoptosis and a reduced ratio of pro- versus anti-apoptosis related proteins. Blood. 90(Suppl 1):1997;520a.
131. Hulette B.C., Banavali S.D., Finke D.P., Gopal V., Preisler H.D. Proto-oncogene expression in subpopulations of cells from leukemia patients. Cytometry. 13:1992;653.
132. Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: Immunostaining of bone marrow biopsies. Leuk Res 1998;22:767.
133. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49.
134. Fenaux P., Jonveaux P., Quiquandon I.et al. p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood. 78:1991;1652.
135. Lai J.L., Preudhomme C., Zandecki M.et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia. 9:1995;370.
136. Jonveaux P., Fenaux P., Quiquandon I.et al. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene. 6:1991;2243.
137. Buhler-Leclere M., Graswohl A., Senn J.P. Occurrence of point mutations in p53 gene is not increased in patients with acute myeloid leukemia carrying an activating N-ras mutation. Br J Haematol. 84:1993;443.
138. Mori N., Wada M., Yokota J.et al. Mutations of the p53 tumour suppressor gene in hematologic neoplasms. Br J Haematol. 81:1992;235.
139. Hatake K, Tomizuka H, Ikeda M et al. The presence of apoptosis in refractory anemia of myelodysplasia. In: Abraham N, editor. Molecular Biology of Haematopoiesis, vol 3. Andover, MD: Intercept, 1994:127.
140. Shetty V., Hussaini S., Borady-Robinson L., Gao X., Dar S., Mundle S., Cartlidge J., Bagai K., Showel M., Andrews C., Akhtar A., Ali A., Mativi B.Y., Venugopal P., Chopra H., Bi S., Gregory S.A., Preisler H., Raza A. Suppression of tumor necrosis factor-alpha induced apoptosis by Flt-3 ligand in myelodysplastic syndromes and HL-60 cells. Blood. 90(Suppl 1):1997;203a.
141. Goossens V., Grooten J., De Vos K., Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA. 92:1995;8115.
142. Shoji Y., Uedono Y., Ishikura H., Takeyama N., Tanaka T. DNA damage induced by tumour necrosis factor-alpha in L929 cells is mediated by mitochondrial oxygen radical formation. Immunology. 84:1995;543.
143. + myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-α concentration. Br J Haematol. 99:1997;625.
144. Maciejewski J.P., Selleri C., Anderson S., Young N. Fas antigen expression in CD34+ human marrow cells is induced by interferon-γ and tumor necrosis factor-α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 85:1995;3183.
145. Gersuk G.M., Lee J.W., Beckham C.A., Anderson J., Deeg J.H. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood. 88:1996;1122.
146. Okada M., Okamoto T., Saheki K., Fuimo Y., Takemoto, Kakisista E. Increased expression of Fas antigen and apoptosis in patients myelodysplastic syndromes. Blood. 90(Suppl 1):1997;202a.
147. Mativi B.Y., Mundle S., Ali A., Bag K., Venugopal, Feldman G., Cartlidge J., Qawi H., Shetty V., Gregory S.A., Raza A. Fas/Fas-L system could be one of the mediators of excessive apoptosis in myelodysplastic syndromes. Blood. 90(Suppl 1):1997;202a.
148. Greenberg P.L., Nichols W.C., Schrier S.L. Granulopoiesis in acute myeloid leukemia and preleukemia. New Engl J Med. 284:1971;1225-1232.
149. Campos L., Sabido O., Viallet A., Piselli S., Guyotat D. Implication of ICE and CPP32 in the in vitro growth defects of committed progenitors from myelodysplastic syndromes. Blood. 90(Suppl 1):1997;521a.
150. Ali A., Mundle S., Ragasa D., Reza S., Shetty V., Mativi B., Cartlidge J., Azharuddin M., Hines C., Raza A. Sequential activation of caspases during spontaneous apoptosis of bone marrow cells in myelodysplasia. Blood. 90(Suppl 1):1997;521a.
151. Negrin R.S., Haeuber D.H., Nagler A., Olds L.C., Donlon T., Souza L., Greenberg P.L. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. Ann Intern Med. 110:1989;976.
152. Negrin R.S., Haeuber D.H., Nagler A., Kobayashi Y., Sklar J., Donlon T., Vincent M., Greenberg P.L. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor. Blood. 76:1990;36.
153. Negrin R.S., Stein R., Vardiman J., Doherty K., Cornwell J., Krantz S., Greenberg P.L. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood. 82:1993;737.
154. Hellstrom-Lindberg E., Birgegard G., Carlsson M.et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anemia in patients with myelodysplastic syndromes. Leuk Lymphoma. 11:1993;221-228.
155. Bradbury D., Zhu Y.-M., Russell N. Regulation of bcl-2 expression and apoptosis in acute myeloblastic leukemia cells by granulocyte-macrophage colony-stimulating factor. Leukemia. 8:1994;786.
156. Rinaudo M.S., Su K., Falk L.A., Halder S., Mufson R.A. Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells. Blood. 86:1995;80.
157. Jacobs A., Janowska A., Caro J.et al. Circulating erythropoietin in patients with myelodysplastic syndrome. Br J Haematol. 73:1989;36.
158. Verhoef G.E., De Schouwer P., Ceuppens J.L., Van Damme J., Goossens W., Boogaerts M.A. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 6:1992;1268.
159. Greenberg P.L., MacKichan M.L., Negrin R., Renick M., Ginzton N. Production of granulocyte colony stimulating factor by normal and myelodysplastic syndrome peripheral blood cells. Blood. 76(Suppl 1):1990;146.
160. Reed J.C., Tsujimoto Y., Alpers J.D., Croce C.M., Nowell P.C. Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science. 236:1987;1298.
161. Greenberg P., Taylor K., Larson R., Koeffler P., Negrin R., Saba H., Ganser A., Jakubowski A., Lamborn K., Brown S. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood. 82(Suppl 1):1993;196a.
162. + progenitor growth and promotes progenitor cell growth via polyamine-like effects. Blood. 90(Suppl 1):1997;520a.
163. List A., Brasfield F., Heaton R.et al. Stimulation of hemopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 90:1997;3364.
164. Raza A., Andric T., Qawi P.et al. Combination of pentoxyfylline, ciprofloxacine and dexamethasone with amifostine improves the ineffective hemopoiesis in patients with myelodysplastic syndromes. Blood. 90(Suppl 1):1997;84a.